Synvista Therapeutics, Inc. Stock Nasdaq

Synvista Therapeutics, Inc. (Synvista), formerly Alteon, Inc., is a product-based biotechnology company engaged in the development of diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease. The Company's lead drug candidate, alagebrium chloride or alagebrium, is an advanced glycation end-product crosslink breaker being developed for diastolic heart failure (DHF). Synvista is also managing a discovery and development program to produce small molecule drugs that mimic the enzyme glutathione peroxidase (GPx). One of the Company’s GPx mimetics, ALT-2074, is in Phase II clinical trials.